Validation of the Individualized Metabolic Surgery score in predicting long-term remission of diabetes after duodenal switch-type procedures.
IMS
SADI‐S
SADS
duodenal switch
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
revised:
13
04
2024
received:
20
03
2024
accepted:
23
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
To validate the Individualized Metabolic Surgery (IMS) score and assess long-term remission of type 2 diabetes (T2D) after duodenal switch (DS)-type procedures in patients with obesity. In addition, to help guide metabolic procedure selection for those patients categorized as having severe T2D. This is a retrospective single cohort study of all patients with T2D and severe obesity, who underwent DS-type procedures at a single institution from December 2010 to December 2018. Study endpoints included validating the IMS score in our cohort and evaluating the impact of DS-type procedures on long-term (≥ 5 years) remission of T2D, especially in patients with severe disease. A receiver operator characteristic curve was used to assess the accuracy of the IMS score using the area under the curve (AUC). The study cohort included 30 patients with complete baseline and long-term glycaemic data after their index DS-type surgery. Twelve patients (40%) were classified with severe T2D, and the distribution of IMS-based severity groups was similar between our cohort and the original IMS study (P = .42). IMS scores predicted long-term T2D remission with AUC = 0.77. Patients with IMS-based severe diabetes achieved significantly higher long-term remission after DS-type procedures compared with gastric bypass and/or sleeve gastrectomy from the original IMS study (42% vs. 12%; P < .05). The IMS score properly classifies the severity of T2D in our study cohort and adequately predicts its long-term remission after DS-type procedures. While T2D remission decreases with more severe IMS scores, long-term remission remains high after DS-type procedures among patients with severe disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
La Sala L, Pontiroli AE. Prevention of diabetes and cardiovascular disease in obesity. Int J Mol Sci. 2020;21(21):8178‐8195.
Thom G, Messow CM, Leslie WS, et al. Predictors of type 2 diabetes remission in the diabetes remission clinical trial (DiRECT). Diabet Med. 2021;38(8):e14395.
Vahibe A, Livia C, Portela R, et al. Diabetes remission after bariatric surgery in patients on glucocorticoids: a pilot study. Surg Laparosc Endosc Percutan Tech. 2021;32(2):236‐240.
Residori L, Garcia‐Lorda P, Flancbaum L, Pi‐Sunyer FX, Laferrere B. Prevalence of co‐morbidities in obese patients before bariatric surgery: effect of race. Obes Surg. 2003;13(3):333‐340.
Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;2014(8):CD003641.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5‐year outcomes. N Engl J Med. 2017;376(7):641‐651.
Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10‐year follow‐up of an open‐label, single‐centre, randomised controlled trial. Lancet. 2021;397(10271):293‐304.
Angrisani L, Santonicola A, Iovino P, et al. IFSO worldwide survey 2016: primary, Endoluminal, and Revisional procedures. Obes Surg. 2018;28(12):3783‐3794.
Hedberg J, Sundstrom J, Sundbom M. Duodenal switch versus Roux‐en‐Y gastric bypass for morbid obesity: systematic review and meta‐analysis of weight results, diabetes resolution and early complications in single‐centre comparisons. Obes Rev. 2014;15(7):555‐563.
Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N. Bariatric surgery worldwide 2013. Obes Surg. 2015;25(10):1822‐1832.
Gebelli JP, Lazzara C, de Gordejuela AGR, et al. Duodenal switch vs. single‐anastomosis duodenal switch (SADI‐S) for the treatment of grade IV obesity: 5‐year outcomes of a multicenter prospective cohort comparative study. Obes Surg. 2022;32(12):3839‐3846.
Andalib A, Safar A, Bouchard P, Demyttenaere S, Court O. Single anastomosis duodenal switch versus classic duodenal switch: long‐term outcomes from a prospective comparative cohort study. Obes Surg. 2023;33(12):3951‐3961.
Clapp B, Ponce J, Corbett J, et al. American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2024;20(5):425‐431.
Powell‐Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984‐e1010.
Aminian A, Brethauer SA, Andalib A, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266(4):650‐657.
Ghusn W, Hage K, Vierkant RA, et al. Type‐2 diabetes mellitus remission prediction models after Roux‐En‐Y gastric bypass and sleeve gastrectomy based on disease severity scores. Diabetes Res Clin Pract. 2024;208:111091.
Aron‐Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced‐DiaRem score improves prediction of diabetes remission 1 year post‐Roux‐en‐Y gastric bypass. Diabetologia. 2017;60(10):1892‐1902.
Lee WJ, Almulaifi A, Tsou JJ, Ser KH, Lee YC, Chen SC. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus: predicting the success by ABCD score. Surg Obes Relat Dis. 2015;11(5):991‐996.
Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C‐peptide, and duration score. Surg Obes Relat Dis. 2013;9(3):379‐384.
Lajeunesse‐Trempe F, Piche ME, Marceau S, et al. Preoperative predictors of type 2 diabetes remission after bilio‐pancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2023. doi:10.1016/j.soard.2023.11.006. Online ahead of print.
Guerron AD, Perez JE, Risoli T Jr, Lee HJ, Portenier D, Corsino L. Performance and improvement of the DiaRem score in diabetes remission prediction: a study with diverse procedure types. Surg Obes Relat Dis. 2020;16(10):1531‐1542.
Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438‐2444.
Sanchez‐Pernaute A, Rubio Herrera MA, Perez‐Aguirre E, et al. Proximal duodenal‐ileal end‐to‐side bypass with sleeve gastrectomy: proposed technique. Obes Surg. 2007;17(12):1614‐1618.
Ghusn W, Ma P, Ikemiya K, et al. The role of diabetes severity scores in predicting disease remission in patients with BMI >50 kg/m(2) undergoing Roux‐En‐Y gastric bypass and sleeve gastrectomy: a multi‐centered study. Surg Endosc. 2023;37(9):7114‐7120.
Chen JC, Hsu NY, Lee WJ, Chen SC, Ser KH, Lee YC. Prediction of type 2 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score. Surg Obes Relat Dis. 2018;14(5):640‐645.
Salminen P, Helmio M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux‐en‐Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319(3):241‐254.
Salminen P, Gronroos S, Helmio M, et al. Effect of laparoscopic sleeve gastrectomy vs Roux‐en‐Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2022;157(8):656‐666.
Prachand VN, Ward M, Alverdy JC. Duodenal switch provides superior resolution of metabolic comorbidities independent of weight loss in the super‐obese (BMI > or = 50 kg/m2) compared with gastric bypass. J Gastrointest Surg. 2010;14(2):211‐220.
Goriparthi RG, Martins A, Yerragorla P, Antanavicius G. Long‐term resolution of type 2 diabetes after biliopancreatic diversion and duodenal switch procedure: a retrospective analysis from a high‐volume institution. Surg Obes Relat Dis. 2022;18(8):1025‐1031.
Kapeluto JE, Tchernof A, Masckauchan D, et al. Ten‐year remission rates in insulin‐treated type 2 diabetes after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2020;16(11):1701‐1712.
Nergaard BJ, Leifsson BG, Hedenbro J, Gislason H. Gastric bypass with long alimentary limb or long Pancreato‐biliary limb—long‐term results on weight loss, resolution of Co‐morbidities and metabolic parameters. Obes Surg. 2014;24(10):1595‐1602.
Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux‐en‐Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open‐label, non‐inferiority trial. Lancet. 2019;393(10178):1299‐1309.
Carlsson LMS, Sjoholm K, Karlsson C, et al. Long‐term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post‐hoc analysis of participants from the Swedish obese subjects study. Lancet Diabetes Endocrinol. 2017;5(4):271‐279.
O'Brien R, Johnson E, Haneuse S, et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann Intern Med. 2018;169(5):300‐310.
Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322(13):1271‐1282.
Bouchard P, Al‐Masrouri S, Demyttenaere S, Court O, Andalib A. Long‐term impact of bariatric surgery on major adverse cardiovascular events in patients with obesity, diabetes and hypertension: a population‐level study. Obes Surg. 2022;32(3):771‐778.
Hage K, Abi Mosleh K, Sample JW, et al. Preoperative duration of type 2 diabetes mellitus and remission after Roux‐en‐Y gastric bypass: a single center long‐term cohort study. Int J Surg. 2024. doi:10.1097/JS9.0000000000001139. Online ahead of print.
Clapp B, Wynn M, Martyn C, Foster C, O'Dell M, Tyroch A. Long term (7 or more years) outcomes of the sleeve gastrectomy: a meta‐analysis. Surg Obes Relat Dis. 2018;14(6):741‐747.
Andalib A, Bouchard P, Alamri H, Bougie A, Demyttenaere S, Court O. Single anastomosis duodeno‐ileal bypass with sleeve gastrectomy (SADI‐S): short‐term outcomes from a prospective cohort study. Surg Obes Relat Dis. 2021;17(2):414‐424.
Souteiro P, Belo S, Neves JS, et al. Preoperative Beta cell function is predictive of diabetes remission after bariatric surgery. Obes Surg. 2017;27(2):288‐294.